SPIRIT-SEMICONDUCTOR
24.2.2021 10:12:07 CET | Business Wire | Press release
Spirit Semiconductor, an innovator in high-performance radio frequency solutions, today announced it will be moving to a new headquarters in Theale, U.K. and will be opening a new satellite office in Leeds, U.K. to tap into the strong radio frequency (RF) monolithic microwave integrated circuit (MMIC) and filter engineering talent in Northern England. The expansion comes on the heels of swift customer adoption and deployment of Spirit Semiconductor’s technology for 5G massive multiple-input and multiple-output (mMIMO) and small cell base stations.
Since the company’s inception in 2020, it has experienced rapid growth, developing a core team of 15 people in less than one year. Located in one of the U.K.’s technology hotbeds, the new office is five times larger than current Spirit headquarters, boasting 9,000 square feet of office space. The new Leeds office will support the company’s plans to expand its product portfolio and enter into other high growth markets.
“When Spirit Semiconductor was founded last year, we were solely focused on creating cutting edge radio frequency products for 5G mMIMO. Currently, our products are being evaluated by customers but the feedback we have received so far has been hugely positive and really provides us with the encouragement we need to branch out into other markets,” said Mark Moffat, managing director of Spirit Semiconductor. “At this rate, we are targeting 65% growth in 2021. This is only the beginning for our company, and I could not be more excited to see what the next year brings by way of innovation and expansion.”
“Massive MIMO architectures change the fundamental building blocks of the RF chain dramatically,” commented Joe Madden, chief analyst at Mobile Experts. “We are experiencing very rapid market growth for some RF components as the base station design adapts to 32T and 64T variations of massive MIMO, with tight performance requirements for RFICs to support a wide range of applications.”
Spirit Semiconductor is looking for the semiconductor industry’s top talent. The company is currently hiring for several positions: principal filter design engineer, principal MMIC design engineer, senior MMIC design engineer and senior analog IC design engineer. For additional information, contact Luke Ord at IC Resources, luke.ord@ic-resources.com , +44 118 907 3070.
“IC Resources is excited to be helping Spirit Semiconductor to identify the right talent to fuel its impressive growth,” commented Kathy Campling, client services director at IC Resources. “Spirit’s strong business plan, exciting product roadmap and generous benefits package are an attractive proposition to potential employees.”
About Spirit Semiconductor Ltd.
Spirit Semiconductor Ltd. is a United Kingdom based company, founded by experts in the radio frequency (RF) semiconductor industry. We are focused on developing high-performance RF products to support the rapid roll out of 5G massive MIMO (mMIMO), small cell base stations and other markets requiring high performance solutions. At Spirit Semiconductor our approach is intelligent innovation, fast implementation and strong team collaboration. We are an aggressive, fast-moving group that is focused on developing compelling products that meet our customers’ needs and timescales, while maintaining a strong team ethic and collaborative spirit. We believe in developing a balanced team that has all levels of experience and fostering an environment where everyone has the opportunity to learn and grow. To learn more, visit www.spiritsemiconductor.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210224005291/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom